>
Switch to:

Allergy Therapeutics Capex-to-Revenue

: 0.06 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Allergy Therapeutics's Capital Expenditure for the six months ended in Jun. 2021 was $-2.61 Mil. Its Revenue for the six months ended in Jun. 2021 was $42.50 Mil.

Hence, Allergy Therapeutics's Capex-to-Revenue for the six months ended in Jun. 2021 was 0.06.


Allergy Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Allergy Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Capex-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.04 0.03 0.03

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Capex-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.02 0.05 0.01 0.06

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Capex-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Capex-to-Revenue falls into.



Allergy Therapeutics Capex-to-Revenue Calculation

Allergy Therapeutics's Capex-to-Revenue for the fiscal year that ended in Jun. 2021 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3.5932678821879) / 118.2762973352
=0.03

Allergy Therapeutics's Capex-to-Revenue for the quarter that ended in Jun. 2021 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.6143057503506) / 42.495091164095
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Rvenue Raio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Allergy Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)